Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Traumatic brain injury and risk of dementia at different levels of cognitive ability and education

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. More precise phenotyping of cluster headache using prospective attack reports

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Acute endovascular reperfusion treatment in patients with ischaemic stroke and large-vessel occlusion (Denmark 2011–2017)

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mid- to late-life migraine diagnoses and risk of dementia: a national register-based follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The influence of prolonged strength training upon muscle and fat in healthy and chronically diseased older adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Functional-structural assessment of the optic pathways in patients with optic neuritis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PURPOSE: Combining different therapies may improve disease control in patients with relapsing-remitting multiple sclerosis (RRMS). This study assessed the efficacy and safety of minocycline added to subcutaneous (sc) interferon (IFN) β-1a therapy.

METHODS: This was a double-blind, randomized, placebo-controlled multicentre study. Within 3 months (±1 month) of starting sc IFN β-1a 44 μg three times weekly, patients with RRMS were randomized to minocycline 100 mg twice daily or placebo, added to sc IFN β-1a, for 96 weeks. The primary efficacy endpoint was the time to first qualifying relapse. Secondary efficacy endpoints were the annualized relapse rate for qualifying relapses, the number of new/enlarging T2-weighted lesions and change in brain volume [magnetic resonance imaging (MRI) was performed only in a few selected centres]. In addition, a number of tertiary efficacy endpoints were assessed.

RESULTS: One hundred and forty-nine patients received minocycline and 155 received placebo; MRI data were available for 23 and 27 patients, respectively. The time to first qualifying relapse did not differ significantly for minocycline versus placebo (hazard ratio 0.85; 95% confidence interval 0.53, 1.35; log-rank = 0.50; P = 0.48). There were no statistically significant differences between the two groups on other efficacy endpoints, although some numerical trends in favour of minocycline were observed. No unexpected adverse events were reported, but more patients discontinued because of adverse events with minocycline versus placebo.

CONCLUSION: Minocycline showed no statistically significant beneficial effect when added to sc IFN β-1a therapy.

Original languageEnglish
JournalEuropean Journal of Neurology
Volume23
Issue number5
Pages (from-to)861-870
Number of pages10
ISSN1351-5101
DOIs
Publication statusPublished - May 2016

ID: 46193691